inPractice® - Ledipasvir

Management of Hepatitis C Infection

Authors: Jordan J. Feld, MD, MPH; Hemant Shah, MD, MScCH HPTE (More Info)
Editor In Chief: Stefan Zeuzem, MD
Last Reviewed: 7/24/18 (What's New)

Summary

Ledipasvir/sofosbuvir is approved by the FDA for treatment of genotypes 1, 4, 5, and 6 HCV^{[FDA Ledipasvir/Sofosbuvir]}and by the EMA for treatment of genotypes 1, 3, 4, 5, and 6 HCV infection in adults and adolescents 12 years of age or older^{[EMA Ledipasvir/Sofosbuvir]}
- Ledipasvir/sofosbuvir approved as stand-alone peginterferon- and ribavirin-free therapy in the United States and in some populations in Europe

Action required

Login now to access all of your entitled content
or
View additional options to gain access to this content

Keywords: Hepatitis C-Treatment